Baird upgraded CVS Health (CVS) to Outperform from Neutral with a price target of $82, up from $71. The firm has growing confidence in a turnaround at the company’s Health Care Benefits segment following the Q2 report. CVS has minimal Medicaid earnings exposure and is exiting the “difficult” healthcare exchange business, the analyst tells investors in research note. Baird upgraded CVS after adjusting its power rankings in managed care.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CVS:
- CVS Health upgraded to Outperform from Neutral at Baird
- CVS vs. UNH: Which Healthcare Stock is a Better Buy After Q2 Earnings?
- Judges reject 2 cases challenging Medicare negotiation, The Hill reports
- CVS Health Earnings Call Highlights Growth Amid Challenges
- CVS Health price target raised to $99 from $95 at TD Cowen